12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Company News  |  Deals

Unigene, GlaxoSmithKline deal

Unigene and GlaxoSmithKline signed a separate deal under which Unigene will conduct development and manufacturing activities related to the active pharmaceutical ingredient and finished drug product for its oral parathyroid hormone (PTH). Unigene will...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >